Interestingly, MGMT methylation is not significantly different between the 2 groups (47% vs 40%), while other key GBM-associated alterations including TERT promoter mutation (71% vs 83%), EGFR amplification (24% vs 36%), and EGFRvIII mutation (12% vs 22%), were significantly less prevalent in CR-mut tumors as compared to CR-WT. This evidence concerns the gene MGMT and glioblastoma.